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INTRODUCTION
Phenothiazines and numerous other chemically related 
compounds, which are normally used for psychopharmaceutic 
purposes, have been shown to have valuable antimicrobial activities 
[1-7]. Th ey are also called non-antibiotics and work either alone or 
synergistically as adjuvants with existing antibiotics. Th ey have gained 
considerable interest because of the need for new chemotherapeutics 
against increasingly drug resistant microbial infections and cancer 
[8-11]. For these reasons, we have focused our research on the 
antimicrobial activity of the phenothiazines, their structural relatives, 
the thioxanthenes and other Central Nervous System (CNS) -active 
compounds [10,12-16]. 
Th ioridazine (TZR) was synthesized in 1951 and commercialised 
by Novartis in 1959 under the trade name of Mellaril™ (or 
Melleril™) where aft er it became a common, long-term treatment of 
schizophrenia [7].
Pioneering work carried out using the severe multi-resistant TB 
strains collected in New York in the late 1980s and the beginning of 
the 1990s by Amaral et al. [17] focussed interest on the antimicrobial 
activity of TZR. An early structure-activity relationship study, 
comparing 18 diff erent phenothiazine derivatives, obtained especially 
promising antimicrobial results using TZR [18]. Together, these 
studies led to TZR being intensively investigated by many laboratories 
all over the world [19]. 
Radhakrishnan et al. [20] tested 316 strains belonging to both 
Gram positive and Gram negative bacteria and showed that in 
addition to TZR being bactericidal against S. aureus and bacteriostatic 
against Vibrio cholera and parahaemolyticus, other Gram negative 
organisms were also aff ected. 
Indicating that several mechanisms may be involved, TZR has 
also been shown to be able to reverse resistance by facilitating the 
elimination of R plasmids from twelve multiple antibiotic-resistant 
bacteria including Escherichia coli (E. coli) and Shigella fl exneri but 
not in S. aureus [20]. 
One of the shortcomings precluding the utilization of TZR is 
that it has been reputed to have cardiotoxic properties [21]. Even 
at low concentrations, TZR was found to have a concentration-
dependent prolongation of the QT interval (an indication of serious 
cardiotoxicity) [22,23]. Th erefore, in 2005, Novartis discontinued 
Mellaril™ (TZR) worldwide, stating that “the benefi t/risk profi le 
of Mellaril™ could no longer meet current clinical and regulatory 
expectations”. Th e manufacturer cited evidence of a connection 
between QT prolongations, cardiac arrhythmias and sudden death in 
patients with schizophrenia [24]. Furthermore, Novartis claimed that 
new and improved antipsychotic treatments had become available. 
Th e antimicrobial eff ects were ignored.
It is essential to analyse this information in detail because 
an unfavourable clinical eff ect would signifi cantly diminish the 
justifi cation for developing TZR further. Side eff ects can be detected 
and described based on the retrospective description of cohorts of 
psychiatric patients. Reilly et al. [21] identifi ed 74 cases meeting the 
study criteria for probable sudden death and 27 cases meeting the 
criteria for confi rmed sudden death. Out of the 74 probable cases, 
seventeen were younger than 65 years and only one patient was 
younger than 50 years. Th is study was based on a total catchment 
population of 1.23 million people. Th e results are in accordance with 
the observations published by Glassman & Bigger who stated that 
“Although sudden death occurs almost twice as oft en in populations 
treated with antipsychotics as in normal populations, there are still 
only 10 – 15 such events in 10,000 person-years of observation” [24]. 
In conclusion, the side eff ect profi le of TZR includes an estimated 
risk of sudden death due to QT prolongation of approximately 5 – 
8 events in 10,000 cases from the normal healthy population. Th e 
TZR data include the notable observation that only one patient was 
younger than 50. In relation to the potential use of TZR for treatment 
of bacterial infections, TZR would be administered for only a few 
weeks (instead of years for psychiatric patients), and this would be 
expected to considerably ameliorate the side eff ect profi le. 
Th is information represents the relevant background for the 
withdrawal of TZR in 2005 for schizophrenia. Th ese facts gain a 
completely diff erent signifi cance in the situation where there are 
growing limitations to antibiotic treatment. In 2015, globally, 10.4 
million people fell ill with TB and 1.8 million died from the disease. 
In the same year an estimated 480,000 people developed Multidrug-
Resistant TB (MDR-TB) or Extensively Drug-Resistant TB (XDR-
TB) and of them, 242,000 died [25]. Expenses for MRSA treatment 
cost billions of dollars alone in the USA [26-27] and the EU have 
estimated that 25,000 persons in the EU have died from antibiotic 
resistant bacteria in 2015 [28]. Th is is not a situation where an older 
drug can be substituted by a newer one with a better side-eff ect 
profi le. We anticipate that a lack of options might designate TZR 
as a potential treatment in situations where the natural course of 
the disease comprises a signifi cantly higher risk of death than that 
attributed to sudden death. In other words, based on current data, 
TZR possesses considerable potential for the treatment of antibiotic 
resistant (and sensitive) microorganisms like Staphylococcus aureus 
and Mycobacterium tuberculosis. Th us, the potential benefi ts of TZR 
outweigh the implied shortcomings, and TZR needs therefore to be 
investigated further.
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Like several other phenothiazines, thioridazine is a racemic 
mixture consisting of two enantiomers comprising a dextrorotary 
(+TZ) and a laevorotatory (–TZ) form (Figure1). Th e experiments 
showing synergistic recovery of antibiotic sensitivity were performed 
with the racemic mixture TZR [15,29-32]. In 2005, Hendricks et al. 
showed that TZR and –TZ (also known as “JEK47”) were able to 
reverse resistance in vancomycin-resistant enterococci and also in 
Methicillin-Resistant and –Sensitive Staphylococcus aureus strains 
(MRSA and MSSA respectively) [10, 15,29]. 
In respect of the cardiotoxicity question, a recent study indicated 
that –TZ has a negligible eff ect on the electrophysiological properties 
of cardiac muscle, while both +TZ and the racemate cause signifi cant 
prolongation of the ventricular Action Potential Duration (APD) 
[16,33]. Th ese prolonging eff ects appear to be caused by a signifi cantly 
higher inhibition of the rapid component of the delayed rectifi er 
potassium current, IKr, by the +TZ [34]. 
Concerning the neurological properties, –TZ also has a less 
challenging CNS pharmacodynamic activity (e.g. weaker blockade of 
dopamine D2-receptors) and is the enantiomer that is concentrated 
in human tissue at higher levels than +TZ [35-37].
Results, obtained using stereochemical analogues and new 
synthesized structures, have pointed to the possibility to separate 
their classical pharmacological activities from their antimicrobial 
eff ects. Micro-gravimetric titration studies of the molar ratios of 
phenothiazine hydrochloride derivatives with various lipids have 
suggested that their ionization potential is related to their sedative 
eff ects. In contrast, their diff erences in lipophilicity to diff erent 
membranes in the cell (i.e. due to variations in phospholipids present 
in these membranes) may be related to non-neuronal physiological 
properties. Th e correlation between the molar ratio and the Fibonacci 
series suggests that similar spiral adducts are formed at water-
phospholipid boundaries (e.g. membranes) irrespective of the actual 
analogue/phospholipid pair tested and that these adducts self-
organize to minimize energy relationships [38]. Th is possibility to 
separate pharmacological and antimicrobial eff ects has thus started a 
search to fi nd analogues with minimal cardiotoxic and neurological 
activities (peripheral and central nervous system) while further 
increasing their antimicrobial potency [16-39].
Additional studies comparing +TZ, –TZ and the racemate 
on 55 diff erent bacteria (both Gram positive and Gram negative) 
showed that –TZ was superior in terms of both its in vitro and in 
vivo effi  cacies. Of relevance to the S. aureus studies presented here, 
–TZ was found to be eff ective on both PAN sensitive strains: ‘Oxford’ 
NCTC 6571 and NCTC 8530, the ATCC strain 25923; as well as the 
resistant strains ML 16, ML 152, ML 266, ML277, ML 329, ML 358, 
ML 422 [40].
Provided that –TZ has at least the same antibacterial activity as 
the racemate, these pharmacological attributes make it a better option 
to reverse resistance or as a “helper compound” in combination with 
antibiotics [8,30]. Th e purpose of this investigation was to extend the 
S. aureus studies, by comparing the antimicrobial activity of racemic 
Th ioridazine (TZR) and the –TZ on selected S. aureus clones which 
are currently of serious concern in Denmark. We have used clones 
isolated from pigs (which are silent carriers) and humans. Th ese 
studies are made more signifi cant by the increasing number of MRSA 
CC398 cases detected. Th e use of +TZ thus has little interest from 
the clinical viewpoint and we therefore have focused on –TZ as a 
potential antibiotic helper compound. Th e aim of this work was thus 
to investigate the antimicrobial effi  cacy of –TZ as compared to the 
racemic mixture using clinically relevant strains and tests.
MATERIALS AND METHODS
Bacterial strains 
Th e MSSA strains used included strain Newman (English 
hospital, 1952, [41]) and ATCC 25293 (US, 1945, Staphylococcus 
aureus subsp. aureus (ATCC® 25923™). Th e MRSA strains employed 
were COL (English hospital, 1966 [42]), 51203 and 51726 (Clinical 
isolates provided by Statens Serum Institute, Denmark (SSI)). Th e 
latter is a member of Clonal Complex (CC) 398 and is considered to 
have originated from pigs [43]. Th e strains were maintained as pure 
cultures in standard media throughout the entire project. Strain SA-
1199B was used for effl  ux inhibition assays [44]. Th is strain has a norA 
promoter region mutation that results in high-level gene expression, 
producing a multidrug effl  ux-related resistance phenotype.
Antimicrobial agents and other chemical reagents
Dicloxacillin (DCX) was obtained from Bristol-Myers Squibb AB, 
and oxacillin was obtained from BioMerieux-Diagnostics. All other 
chemicals were purchased from Sigma Aldrich. 
Media
Mueller-Hinton II 90 mm plates were purchased from SSI, 
Denmark and used for the E-test. E-test strips were obtained from 
Biomerieux. Brain Heart Infusion (BHI) broth was obtained from 
Oxoid, Mueller-Hinton (MH) broth from Merck, and granulated 
Difco agar (BD) were used for subculture and maintenance of all the 
bacterial strains investigated.
Isolation of –TZ
Clinically prescribed Th ioridazine (TZR) hydrochloride is a 
racemic mixture of equal amounts of the (+) and (–) enantiomers 
with an asymmetric carbon at position 2 of the piperidyl ring 
(Figure 1). Th e enantiomers were separated by resolution according 
to the procedure described by Bourquin et al. [45]. Briefl y, TZR 
was fi rst converted to the free base. –TZ was obtained by fractional 
crystallisation out of acetone before being converted back into the 
hydrochloride. 
Using optical rotation analysis only [46,47] we estimate that the 
purity of this batch to be approximately 80%. Robert has shown that 
the pure – enantiomer (free base) has a specifi c rotation of -37° in 
ethanol at 20°C while the + enantiomer has +33° [48]. Subsequent 
Enantiomeric Excess (EE) analysis was determined by using an 
Aurora Fusion A5/Agilent SFC system operating at 3 ml/min at 
40°C and 150 bar backpressure. Th e column was a ChiralpakAD3 
3m (150 x 4.6 mm). Th e eluent was CO2 (50%) and ethanol + 0.1 % 
diethylamine (50%). Th e – enantiomer purity was found to be 68%.
Thioridazine (+)                          Thioridazine (-) 
Figure 1: The structures of the two enantiomers of thioridazine (+) and (–).
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Minimal Inhibitory Concentration (MIC) determined on 
solid media by E-test
Th e minimal inhibitory concentration of DCX was determined 
by E-test according to the manufacturer’s instructions (Biomerieux). 
A colony was picked with a 1 μl white inoculation stick (McFarland 
0.5) and suspended in 4.5 ml sterile 0.9% w/v sodium chloride and 
spread on a Mueller-Hinton II 90 mm plate (SSI) with a sterile swab 
and left  to dry for approximately 20 min aft er which an E-test strip 
was placed on the plate. Th e plate was incubated for 20 hours at 35°C 
and the MIC was read the next day according to the manufacturer’s 
instructions. 
MIC determined by the tube dilution technique
For all strains, MICs for TZR, +TZ, and –TZ were determined 
by the tube dilution technique [49]. A series of two-fold dilutions 
were prepared and the MIC was determined aft er incubation for 20 
hours as the lowest concentration that inhibited growth (Table 1). 
Th e experiments were repeated twice. 
Growth and viability of test bacteria in liquid medium
Growth and viability assays were performed as described by 
Poulsen et al. [28]. In order to perform viability assays, sub-inhibitory 
concentrations of the TZR forms and DCX were determined by 
growth experiments in liquid media. An overview of the sub-
inhibitory concentrations of the TZR forms and DCX found by growth 
experiments are presented in table 1. For viability experiments, early 
exponential phase bacteria were exposed to the determined sub-
inhibitory concentrations of thioridazine (TZR or –TZ) and DCX 
alone or in combination. Th e number of colony forming units was 
determined by 10 fold dilutions in saline buff er and plated on MH 
agar plates. Th e experiments were repeated twice.
Efﬂ ux inhibition assay
Ethidium Bromide (EtBr) is a substrate for many bacterial 
multidrug effl  ux pumps, including NorA. Th e effi  ciency of these EtBr 
pumps can be assessed fl uorometrically by the loss of fl uorescence 
over time from EtBr-loaded cells. SA-1199B was loaded with EtBr as 
previously described, and the eff ect of varying concentrations of TZR, 
+TZ, and –TZ on EtBr effl  ux was determined to generate a dose–
response profi le for each compound [44,50]. Results were expressed 
as percentage reduction of the total effl  ux observed for test strains in 
the absence of inhibitors. Th e 50% inhibitory concentration (IC50) 
for test compounds was determined by inspection of dose-response 
plots.
Dopamine receptor afﬁ nity assay
Human dopamine D2 receptors were expressed in COS7 cells. 
Membranes were prepared from COS7 cells aft er transient transfection 
with pcDNA2 plasmid expressing the human dopamine D2 receptor 
using the Lipo2000 transfection protocol (Invitrogen) as described 
previously [17]. Th e affi  nity of –TZ and +TZ to the D2 receptor was 
measured in buff er (25 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.2 
mM CaCl2, 1.2 mM MgSO4, pH 7.4) by competitive binding using 
[3H]-Raclopride. Th e measurements were performed in 96 well plates 
in a volume of 400 μL, at a concentration range from 0.1 – 2000 nM 
(10 determinations in triplicate). Th e binding mixture was incubated 
for 1 hour at room temperature and subsequently fi ltered through 
GF/B fi lters using a Tomtec cell harvester. Aft er drying, the fi lters 
were saturated with Meltilex scintillator and counted in a Perkin 
Elmer Micro beta counter.
RESULTS
Th ioridazine has been shown to have non-antibiotic properties 
but its clinical introduction (for this indication) has been prohibited 
because of cardiotoxic side eff ects. Recent results have shown that 
the laevorotatory enantiomer (–TZ or JEK47) has been shown to 
be less toxic [33]. Th erefore, the task remaining (and the goal of the 
experiments presented here) is to show that –TZ is as potent a non-
antibiotic as the racemate TZR using clinically relevant MSSA and 
MRSA strains.
Towards this goal, we fi rst determined the Minimal Inhibitory 
Concentration (MIC) values for TZR and –TZ for the MSSA Newman 
strain. Th ese MIC values were found to be 64 mg/L for both drugs 
when determined by the tube dilution technique. Th e E-test MIC 
values of DCX were 1 mg/L for the Newman strain and 2 mg/L for 
S. aureus ATCC25923, and for S. aureus COL and strain 51203 were 
>256 mg/L and 16 mg/L for strain 51726 (Table 1).
Exponentially growing Newman strain bacteria (initially at an 
OD600 of 0.2) were exposed to concentrations of 8, 12, 16, 20, 24, 28, 
and 32 mg/L of each drug in order to compare the antimicrobial eff ect 
of –TZ and TZR. Aft er 4 hours the optical densities were measured at 
600 nm (OD600) and the data were used to construct dose-response 
curves for each compound. –TZ and TZR had IC50 values of 25.2 and 
29.8 mg/L respectively. Th us these data revealed –TZ is a modestly 
more-potent antimicrobial agent than TZR (Figure 2). 
Th ioridazine and DCX have been previously suggested to exhibit 
synergistic anti-bacterial eff ects [51,52]. Th e next step of our analysis 
was to investigate whether the –TZ and TZR also exhibit diff erent 
synergistic eff ects when combined with the antibiotic DCX. Bacterial 
strains were grown in the presence of either single drug or in drug 
combinations and compared to untreated controls grown in media 
alone. Sub-inhibitory concentrations (i.e. the highest concentration 
which did not signifi cantly aff ect the growth of S. aureus in liquid 
media) were determined for the two compounds (TZR and –TZ) 
by viability assays. Th is was determined to be 16 mg/L for all strains 
(Table 1). Similarly, the sub-inhibitory concentrations of DCX were 
determined to be 0.04 mg/L for strain Newman, 0.0625 mg/L for S. 
aureus ATCC25923, 16 mg/L for COL, 32 mg/L for strain 51203 and 
0.125 mg/L for strain 51726. Th e use of sub-inhibitory concentrations 
facilitates the identifi cation of synergistic eff ects.
Table 1: Strains used in the present study, the MIC values determined and the 
concentrations of the drugs chosen for viability assays.
Minimal inhibitory 
concentration (mg/L) 
determined on solid media a)
Sub-inhibitory 
concentrations (mg/L)
used in viability assays b)
Strain TZR –TZ DCX TZR –TZ DCX
MSSA
Newman 64 64 1 16 16 0.04
ATCC25923 64 64 2 16 16 0.0625
MRSA
COL 64 64 >256 16 16 16
51203 64 64 >256 16 16 32
51726 64 64 16 16 16 0.125
a. MIC values for TZR and –TZ were determined by two-fold dilutions. MIC for 
the DCX was determined by E-test.
b. Thioridazine (TZR) and dicloxacillin (DCX) concentrations used in viability 
assays in mg/L.
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Th e results obtained showed that the presence of neither 
thioridazine derivative alone at their sub-inhibitory concentrations 
aff ected the bacterial growth as determined by CFU/ml (Figure 3: 
racemic Th ioridazine, TZR ⧠ or (–)-thioridazine, –TZ Δ). When 
grown in DCX alone, all 5 test strains were slightly inhibited aft er 
4 hours by 1 log or less (Figure 3: ⨯). However, when grown in 
the presence of DCX combined with either of the thioridazine 
formulations, CFU/mL was reduced compared to the control by 
respectively at least 1, 3.5, 3, and 2.5 log10 CFU/ml for S. aureus 
strains: Newman, ATCC25923, COL and 51203. In the 51726 CC398 
strain, the reduction in CFU/mL was as high as 4.5 log10 CFU/mL. 
Th is showed a clear synergistic action of the combination of DCX 
and thioridazine. Similar bactericidal results were obtained when 
either TZR or –TZ were used showing that there were no signifi cant 
diff erences between them.
Strains Newman, ATCC 25923 and COL re-initiated growth 
within 9-22 hours (data not shown) while strains 51203 and 51726 
re-initiated growth aft er 4-5 hours. We suggest that this is caused 
either by the instability of thioridazine, which is light-sensitive [53] 
4.5 
4 
3.5 
3 
2.5 
2 
1.5 
1 
0.5 
0 
0          8         12        16        20        24        28        32 
mg/L 
OD
60
0 
Figure 2: Dose-response curves of thioridazine racemic (TZR) and 
thioridazine (–) (–TZ (JEK47)). At OD600 0.2 a culture of MSSA strain 
Newman was exposed to various concentrations of TZR or –TZ (0 – 32 mg/L). 
The OD600 was measured after 3.7 hours of exposure is presented. Black 
bars; TZR, white bars; –TZ. The experiments were repeated twice and one 
set of data is presented. The raw data for ﬁ gure 2 and data for additional time 
points (0.65, 1.1, 1.67, 2.7, 3.7, 4.65, 5.7 and 6.65 hours) can be found in the 
supporting information ﬁ le S1_ﬁ gure_2.pdf.
Figure 3: Viability assays of ﬁ ve Staphylococcal strains. Two MSSA strains (Newman and ATCC25293) and three MRSA strains (COL, 51203 and 51726). 
Bacterial cultures grown to OD600 0.2 was exposed to drugs either alone or in combination. As a control, bacteria were grown in media alone. The experiments were 
repeated twice and one set of data is presented. Control, ; thioridazine racemic (TZR), ; (–)-thioridazine (–TZ), ; dicloxacillin (DCX), x; thioridazine racemic 
(TZR) and DCX ; (–)-thioridazine (–TZ) and DCX, . The raw data for ﬁ gure 3 can be found in the supporting information ﬁ le S2_ﬁ gure_3.pdf.
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or heterogeneity of the bacterial isolates. Th e more heterogenic, the 
more likely that a few bacteria will continue growth, unaff ected by 
the single dose treatment because they are more drug-resistant. When 
treating patients for bacterial infections, drugs are administered 
repeatedly and thus growth re-initiation is not expected to be an issue. 
One of the most common strategies that cells use when they 
develop multidrug resistance is to reduce drug accumulation by 
increasing the eff ectiveness of their effl  ux pumps. Th ioridazine has 
been shown to inhibit the expression and activity of these effl  ux 
pumps [54-56]. Our next step was therefore to determine whether 
TZR, +TZ, and –TZ diff ered in their eff ectivity for inhibiting these 
pumps.
Th e effl  ux inhibition assay test strain SA-1199B showed MICs 
of 50 mg/L for all test compounds. Effl  ux inhibition assays revealed 
IC50 values of 9, 9, and 5 μM against SA-1199B for TZR, +TZ, and 
–TZ, respectively (data not shown). Th ese values correspond to 
concentrations of 3.7, 3.7, and 2.0 mg/L, respectively, and revealed 
that NorA effl  ux pump inhibition occurs at concentrations of less 
than 10% of the respective MICs as refl ected by IC50/MIC ratios of 
0.07, 0.07, and 0.04, respectively. –TZ is slightly more potent than 
both TZR and +TZ in inhibiting the NorA effl  ux pump.
Since all antipsychotic drugs bind to the dopamine receptor D2, 
the fi nal question we addressed was whether –TZ and +TZ bound 
equally to this receptor. Membranes were prepared from COS7 cells 
expressing Dopamine Receptor 2 (D2R) and their binding affi  nity 
measured by competitive binding with [3H]-Raclopride.
Th e affi  nity of –TZ was measured to 38.8 nM (SE ± 6.3) and that 
of +TZ to 11.3 nM (SE ± 3.7) to the human D2 receptor. Th us –TZ 
has a 3-fold lower affi  nity for the D2 receptor than +TZ (P = 0.0015). 
–TZ would therefore be expected to have a weaker antipsychotic side-
eff ect.
DISCUSSION
Multiple drug resistance is a serious and growing clinical 
problem. Non-antibiotics like Th ioridazine (TZR) have the potential 
to sensitize antibiotic resistant bacteria and ‘re-activate’ existing 
antibiotics. Despite this, they are not currently widely used. 
TZR was withdrawn from the market because of an estimated risk 
of sudden death due to QT prolongation of approximately 5-8 events 
in 10,000 cases (a doubling of the occurrence of this in the healthy 
population). In contrast, there are several reports indicating the value 
of TZR for treating Tuberculosis (TB) [57-60]. Th e potential benefi t 
of using TZR as a treatment for TB may be as high as curing 11 out 
of 17 patients [61].
Considering that: 1.8 million died of TB and a further 242,000 
died of multidrug-resistant or extensively drug-resistant TB [25] 
globally in 2015 and that MRSA treatment cost billions of dollars 
alone in the USA [26,27], there is a pressing need to elucidate the 
clinical utility of TZR. 
Th e experiments presented in this manuscript show that 
combinations of TZR and–TZ together with DCX are equally 
eff ective. In other words, selecting the –TZ enantiomer does not 
compromise its activity. In addition we demonstrate that –TZ binds 
with lower affi  nity to the dopamine 2 receptor, indicating that this 
formulation might provide therapeutic benefi t with reduced side 
eff ects. Th is strengthens the potential for future application of 
combined treatment using –TZ and classical antibiotics. Th ese are 
important arguments needed to make an informed decision as to 
whether to use –TZ as a non-antibiotic against MRSA (and other 
microorganisms) in the clinic.
In the following discussion we therefore consider three diff erent 
aspects of TZR and –TZ which are unclear from the literature. 
Th ese are: 1) the apparent discrepancies relating to TZR; 2) our 
current knowledge of the mode of action of TZR and –TZ; and 3) 
pharmacokinetic aspects of TZR and –TZ. 
Discrepancies relating to TZR concentrations
Our group has previously shown that TZR increases the antibiotic 
susceptibility of MRSA and MSSA strains [15,31,32]. Th e estimated 
MICs in the paper presented by Radhakrishnan et al. [20] are much 
higher (up to 800 mg/L) for some of the S. aureus strains and in 
contrast to data presented here (MIC of 64 mg/L). Th e explanation 
for this might lie in a technical issue. In the Radhakrishnan study, 
TZR was mixed with molten agar (50ᴼC) which may have caused its 
chemical breakdown because phenothiazines are thermolabile and 
can only withstand temperatures up to 40ᴼC.
We have previously investigated the in vitro antimicrobial 
activity of racemic TZR in both sensitive and resistant staphylococci 
[15,31,32,62,63]. In the current study, we have confi rmed that –
TZ has the same potent antimicrobial activity as the racemate on a 
spectrum of S. aureus strains exhibiting very diff erent levels of drug 
resistance (Table 1). Th e dose-response curves in the viability assays 
showed that –TZ had a slightly better antimicrobial eff ect than TZR 
at concentrations greater than 20 mg/L, (Figure 3). Unexpectedly, S. 
aureus strain 51726 was the most sensitive in the synergy/reversal of 
resistance assay. Th is strain was isolated from a clinical case of an 
infection in man from the pig clone CC398. Th e signifi cance of this 
is unknown, but could be due to genetic diff erences between this and 
other CC clones, as seen previously [32]. With a view to reducing 
nosocomial bloodstream infections, catheters were loaded with 
DCX alone or in combination with TZR. While pigs demonstrated 
severe toxicity towards the normal doses of DCX / TZR combination 
(possibly due to drug-drug interactions), reduced doses resulted in a 
signifi cant decrease in the frequency of MSSA infections [64].
Mode of action of TZR
TZR was claimed to potentiate the eff ect of DCX in all test 
isolates comprising both sensitive and resistant staphylococci [32,52], 
indicating that the mechanism is independent of the resistance 
phenotype or expression of virulence genes [62]. Recent data suggests 
that TZR exerts its eff ect by weakening the cell wall. TZR has been 
shown to cause major changes in expression of many genes involved 
in peptidoglycan biosynthesis [63]. Muropeptide analysis of the 
MRSA strain USA300 showed that the peptidoglycan was depleted 
for glycine indicating that TZR could interfere with the formation 
of the pentaglycine branches and lead to a dysfunctional cell wall. 
In addition, insertion of phenothiazines into the interfacial region 
of membranes leads to signifi cant membrane expansion [65]. Th e 
induced splaying of the diacyl chains of phospholipids would result 
in a change in its physical properties, possibly interfering with effl  ux 
pump activity [38].
Effl  ux pump inhibition data revealed that all compounds tested 
(TZR, +TZ, and –TZ) were relatively similar in their ability to interfere 
with NorA function. Th e fact that 50% pump inhibition occurred at 
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concentrations well below the MIC (IC50/MIC ratios of less than 
0.1) suggests that this activity is not directly related to antibacterial 
eff ects. Exposure of SA-1199B to a 30 μM concentration of the related 
compound prochlorperazine resulted in a modest depolarization 
of the cell membrane [9]. However, the IC50 for prochlorperazine 
against SA-1199B was only 9 μM. While these data suggest that direct 
pump inhibition is probable, it remains possible that indirect eff ects 
such as membrane depolarization or other changes in membrane 
functionality may contribute to the inhibition of pump activity. 
Pharmacokinetic aspects of TZR and –TZ
Th e achievable plasma concentration of TZR in humans is only 
0.5 mg/L: hence its potency as an adjuvant drug against MRSA has 
been questioned [66]. However, it has been demonstrated that human 
macrophages concentrate the drug up to 100 times thus providing 
a possibility for its clinical utility [57,58,67-69,70]. Considerably 
higher up-concentrations may occur in the cell membranes due to 
the diff erential lipophilicity of TZR in diff erent phospholipids [38]. 
Th erefore, TZR may reach the concentrations within phagocytic cells 
that are required for it to function as an adjuvant drug to DCX. Th is 
has already been seen with XMDR TB [71]. Macrophages have not 
shown any toxic responses. Liver toxicity and other pharmacokinetic 
parameters could be determined in vitro using human in vivo mimetic 
3D hepatocyte cultures [72].
Th e usual dosage of TZR used to treat schizophrenia was 10 – 
75 mg per day for mild cases, and up to 600 – 800 mg per day for 
severely disturbed patients. Several studies have demonstrated the in 
vivo potential of TZR and –TZ for treating not only MRSA but also S. 
typhimurium and TB. Th ey illustrate that a clinically achievable dose 
can result in a signifi cant improved survival rate [32,69,73].
A murine model of latent TB has been used to demonstrate that 
thioridazine treatment, in combination with isoniazid, can achieve 
complete clearance of the bacillus as early as 24 weeks [74].
Abbate et al. [61] performed a clinical intervention study on 
TB patients based on the off -label use of TZR in combination with 
linezolid and/or moxifl oxacin. In that study, TZR was initially 
administered at a daily dose of 25 mg; thereaft er the dose was 
increased by 25 mg weekly until it reached 200 mg/day. Th e drug was 
only used on inpatients, initially under strict cardiac monitoring in 
order to safeguard against eventual cardiac adverse events. Aft er the 
end of the study 11 out of 17 patients met the cure criteria. 
We demonstrate here that –TZ (JEK47) has a signifi cant 
antimicrobial activity. Th is is similar to the racemic TZR and in 
some situations more potent. Taken together with the diminished 
or excluded side eff ects (reduced cardiotoxic eff ect and lower 
dopamine 2 receptor affi  nity) and the preferential concentration 
of the –TZ enantiomer in human tissue, this strengthens the case 
for implementing –TZ/antibiotic combined treatment strategies 
to combat antibiotic resistance. Th e microorganisms targeted need 
not only be MRSA but should also include S. typhimurium and TB 
[30,40,51,75,76]. It thus appears that, as with ‘methylene blue’ (one 
of the fi rst phenothiazines identifi ed) [61,77], the story of these 
derivatives has turned full circle and we are again standing in the 
clinic with a potentially valuable antimicrobial agent [12,78]. 
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